This study suggested that Tan IIA may act as an effective antitumor agent to induce survivin degradation in CRC cells, which provided a novel avenue for the combination of survivin inhibitors and traditional chemotherapeutic agents to overcome chemoresistance with aims to improve therapeutic outcomes in patients with CRC. Here, BIRC5 is linked to colorectal carcinoma.